5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation. |
|
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors |
|
The Activity of JmjC Histone Lysine Demethylase KDM4A is Highly Sensitive to Oxygen Concentrations |
|
Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. |
|
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases |
|
Development of homogeneous luminescence assays for histone demethylase catalysis and binding. |
|
Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding. |
|
Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion. |
|
Formaldehyde quantification using ampicillin is not selective |
|
Frontiers in epigenetic chemical biology, 5 June 2018: |
|
Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets. |
|
Human histone demethylase KDM6B can catalyse sequential oxidations |
|
Hypoxia and hypoxia mimetics differentially modulate histone post-translational modifications |
|
Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars |
|
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity |
|
In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs) |
|
Inhibitors of both the N-methyl lysyl- and arginyl-demethylase activities of the JmjC oxygenases. |
|
Investigating d-lysine stereochemistry for epigenetic methylation, demethylation and recognition. |
|
Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases |
|
Is JmjC oxygenase catalysis limited to demethylation? |
|
KDM3A coordinates actin dynamics with intraflagellar transport to regulate cilia stability |
|
KDM4A regulates HIF-1 levels through H3K9me3. |
|
Light-driven post-translational installation of reactive protein side chains |
|
Linking of 2-oxoglutarate and substrate binding sites enables potent and highly selective inhibition of JmjC histone demethylases |
|
Lysine-241 has a role in coupling 2OG turnover with substrate oxidation during KDM4-catalysed histone demethylation. |
|
Mechanistic and structural studies of KDM-catalysed demethylation of histone 1 isotype 4 at lysine 26 |
|
Metampicillin is a cyclic aminal produced by reaction of ampicillin with formaldehyde |
|
Modulating carnitine levels by targeting its biosynthesis pathway - selective inhibition of γ-butyrobetaine hydroxylase |
|
Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. |
|
Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system. |
|
Mutations to metabolic enzymes in cancer herald a need to unify genetics and biochemistry. |
|
The N-terminal domain of a tick evasin is critical for chemokine binding and neutralization and confers specific binding activity to other evasins. |
|
Non-competitive cyclic peptides for targeting enzyme-substrate complexes. |
|
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. |
|
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases |
|
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor |
|
Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. |
|
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. |
|
The pharmacogenetics of NAT: structural aspects. |
|
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells |
|
Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors |
|
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors |
|
Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition |
|
Selective recognition of the di/trimethylammonium motif by an artificial carboxycalixarene receptor. |
|
Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. |
|
Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases |
|
Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A. |
|
The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid |
|
Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates |
|
Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates. |
|
Synthesis and anticancer activities of 6-amino amonafide derivatives. |
|
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer |
|
Targeting histone lysine demethylases - progress, challenges, and the future |
|
Tetracyanoresorcin[4]arene selectively recognises trimethyllysine and inhibits its enzyme-catalysed demethylation |
|
Thioether Macrocyclic Peptides Selected against TET1 Compact Catalytic Domain Inhibit TET1 Catalytic Activity. |
|
Yeast surface display identifies a family of evasins from ticks with novel polyvalent CC chemokine-binding activities |
|